<DOC>
	<DOC>NCT00400855</DOC>
	<brief_summary>Inhaling AMP causes an inflammatory response in the lung. This study will investigate whether 5-days of treatment with fluticasone propionate protects the lung from responding to the AMP in this way.</brief_summary>
	<brief_title>Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatment With Fluticasone Propionate</brief_title>
	<detailed_description>A randomised, double-blind, placebo-controlled, incomplete block, 4-period crossover study to investigate the effects of 5-day repeat inhaled doses of fluticasone propionate (BID, 50-2000 mcg) on airway responsiveness to adenosine-5'-monophosphate (AMP) challenge when delivered after the last dose in mild asthmatic subjects</detailed_description>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Female of nonchildbearing potential Using appropriate contraception. Mild asthmatic, non (or ex) smokers. Has inflammatory response to AMP. Otherwise healthy, not using any steroids. Have a history of lifethreatening asthma, defined as an asthma episode, which required intubation and/or was associated with either hypercapnea, respiratory arrest or hypoxia seizures. Have a known sensitivity to corticosteroids. Have a history of milk protein allergy. Test positive at the screening visit for hepatitis B or C or HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>AMP challenge</keyword>
</DOC>